依达拉奉联合神经节苷脂治疗老年急性脑梗死的临床疗效及安全性评价

Effect and safety of edaravone combined with ganglioside in treatment of acute cerebral infarction of elderly patients

目的评价依达拉奉联合神经节苷脂治疗老年急性脑梗死的临床疗效、对炎症因子的影响及安全性。方法将74例老年急性脑梗死患者随机分为试验组36例和对照组38例。2组患者入组后均予以抗凝、降压及改善微循环等基础治疗。试验组给予依达拉奉30 mg+0.9%氯化钠250 m L静脉点滴,每日2次,同时给予神经节苷脂60 mg+0.9%氯化钠250 m L静脉点滴,每日1次。对照组给予血栓通200 mg+0.9%氯化钠250 m L静脉点滴,每日1次。2组患者疗程均为4周。疗程结束后1周,评价2组的临床疗效及肿瘤坏死因子α、C反应蛋白和白细胞介素-6的变化。结果试验组总有效率91.67%显著高于对照组71.05%(P<0.05)。治疗后,2组的肿瘤坏死因子α、C反应蛋白及白细胞介素-6水平均较治疗前显著降低(P<0.05),且试验组治疗后降低更为显著(P<0.05)。2组患者不良反应发生率差异无统计学意义(P>0.05)。结论依达拉奉联合神经节苷脂治疗老年急性脑梗死的临床疗效确切,可显著降低患者体内炎症因子水平。

Objective To evaluate the clinical effect of edaravone com-bined with ganglioside in treatment of acute cerebral infarction of elderly patients and its effect on inflammation factors.Methods A total of 74 cases of acute cerebral infarction were included in this study from Sep-tember 2012 to November 2014 and randomized divided into treatment group（n=36）and control group（n=38）.All the included patients were given basic treatment such as anticoagulation and depressurization regi-men.Patients in the treatment group were administered with edaravone 30 mg＋0.9% sodium chloride 250 mL through intravenous transfusion plus ganglioside 60 mg＋0.9 sodium chloride 250 mL intravenous trans-fusion.Patients in the control group were administered Xue Shuan Tong 200 mg＋0.9%sodium chloride 250 mL through intravenous transfusion. The treatment lasted for 4 weeks in two groups.One week after treatment, the data of clinical efficacy, tumor necrosis factor α（ TNF -α） , C-reactive protein and interleukin-6 were compared between the two groups.Results The total efficacy were 91.67% and 71.05% in the treatment and control group （ P 〈0.05 ） . The inflammation factors （ TNF-α, C-reactive protein and interleukin -6 ） were significantly decreased after treatment（P〈0.05）.And the adverse event incidence rate was not statistically different between the two groups（P〉0.05）.Conclusion Significant clinical efficacy is found in the regimen of edaravone combined with ganglioside for treatment of acute cerebral infarction in elderly patients and the inflammation factors can be significantly decreased.